GE Vernova stock rises as $1,087 target lands, but “oversupply” talk clouds the trade
13 January 2026
1 min read

GE Vernova stock rises as $1,087 target lands, but “oversupply” talk clouds the trade

New York, January 13, 2026, 13:22 EST — Regular session

  • GEV shares jump almost 2% after a new top Wall Street price target fuels bullish momentum
  • A recent downgrade highlights the risk that fresh turbine supply might dampen the rally
  • Attention shifts to Jan. 28 earnings, with investors watching for updates on orders, margins, and guidance for 2026

Shares of GE Vernova climbed Tuesday, boosted by a fresh bullish price target, even as investors weighed caution over rising competition. The stock gained 1.9%, hitting $651.92 in early afternoon trading, after briefly reaching $659.04.

This shift is significant as GE Vernova now serves as a stand-in for the race to boost power generation amid rising electricity demand from data centers and electrification. Following a strong rally, the stock’s price action has begun to reflect sentiment shifts more than daily fundamental changes.

With the quarterly report due later this month, there’s little room left for surprises. Investors will be watching closely for signs that orders and margins are holding pace with rapidly shifting expectations.

GLJ Research’s Austin Wang raised his 12-month price target to $1,087 from $805, maintaining a buy rating. However, he flagged growing caution on the short-term outlook, citing “limited positive catalysts” and a “negative rate of change for data center headline risk.” (TipRanks)

Not everyone buys the straightforward narrative. Baird’s Ben Kallo dropped the rating to hold from buy and slashed his price target to $649 from $816, flagging that new capacity could ease the tight turbine market as competitors like Doosan and Caterpillar step in, Barron’s reported. The outlet also noted GLJ’s 2028 EBITDA estimate at $13.8 billion, surpassing Wall Street’s roughly $11 billion consensus. (Barron’s)

GE Vernova’s shares surged 2.7% Monday, bouncing back after last week’s 8.5% drop triggered by Baird’s downgrade. The jump came on the heels of GLJ raising its price target to $1,087—the highest on Wall Street, according to Investors Business Daily. (Investors)

GE Vernova deals in gas turbines, wind turbines, and grid equipment—the essential gear for power generation and transmission. Since orders for major turbines are typically booked years before delivery, the market often overreacts to any sign that demand is accelerating or slowing down.

The issue hinges more on timing than the trend itself. Locking in capacity quickly helps keep factories humming and supports prices, while hesitating risks revealing how fast supply floods in when rivals spot attractive margins.

The downside scenario is straightforward. Should data center expansions stall, grid connections fall behind, or fresh supply come online quicker than anticipated, the market could swing from shortage to surplus, squeezing both prices and profits.

GE Vernova plans to announce its fourth-quarter and full-year 2025 earnings on Wednesday, Jan. 28, before markets open. A webcast with CEO Scott Strazik and CFO Ken Parks will follow at 7:30 a.m. ET. (GE Vernova)

Stock Market Today

  • ABBV inks drug pricing deal with Trump, joins PD-1xVEGF bandwagon
    January 13, 2026, 2:32 PM EST. AbbVie said it signed a U.S. pricing agreement with the Trump administration to cut list prices to match those in comparable developed markets, backing the MFN proposal. The deal includes a three-year exemption from import tariffs on pharmaceutical ingredients if AbbVie expands U.S. manufacturing, and a pledge to invest $100 billion over the next decade in domestic R&D and capital. The government says 16 of 17 large drugmakers have reached similar accords; Regeneron remains in talks. In a separate release, AbbVie agreed to an exclusive license with RemeGen for its PD-1xVEGF bispecific, RC148. AbbVie will pay an upfront $650 million and up to $4.95 billion in milestones, plus royalties, for rights outside Greater China. RC148 is in phase II in China, with potential in NSCLC and CRC. Competitors include Summit, BioNTech/Bristol Myers, Merck and Pfizer pursuing PD-1/VEGF programs.
Why Procter & Gamble stock is holding up as Wall Street dips ahead of earnings
Previous Story

Why Procter & Gamble stock is holding up as Wall Street dips ahead of earnings

Seadrill Limited stock jumps 7% as oil rally blunts Citi downgrade
Next Story

Seadrill Limited stock jumps 7% as oil rally blunts Citi downgrade

Go toTop